This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (9)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Arch Intern Med. 2001;161:125.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Clopidogrel bisulfate was recently approved by the US Food and Drug Administration for the reduction of ischemic events in patients with recent myocardial infarction, stroke, and peripheral arterial disease, with no added risk for neutropenia.¹ We report an initial case of severe febrile pancytopenia after clopidogrel use.

A 90-year-old woman was monitored for cardiac failure and atrial fibrillation and treated with digoxin and aspirin since 1997. In December 1999, she presented with recurrent episodes of ischemic stroke, so clopidogrel treatment (75 mg/d) was initiated (aspirin treatment was stopped). Twenty days after the introduction of clopidogrel, she was admitted to a hospital because of somnolence and fever (temperature, >39°C) with chills. There was no clinical evidence of focal sepsis. Hematologic findings disclosed severe pancytopenia (hemoglobin, 85 g/L; neutrophil count, 0.9 x 10⁹/L; and platelet count, 100 x 10⁹/L). Laboratory test results revealed an inflammation (C-reactive protein >180 mg/L). Blood . . . [Full Text of this Article]

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis
Schachter et al.
CMAJ 2001;165:1475-1488.
ABSTRACT | FULL TEXT